Valencia, CA-based physics company Nusano has opened a new flagship radioisotope production facility in West Valley, UT, to support domestic radiopharmaceutical manufacturing.
The 190,000 sq ft facility can produce up to 12 different radioisotopes simultaneously, according to the firm. New supplies of radioisotopes are urgently needed for new and emerging cancer diagnostics and therapeutics.
Nusano noted that existing medical radioisotope supply chains are often strained and pose a risk to patient care, clinical trials, and ongoing drug development. The facility addresses supply chain bottlenecks, it said.
In January, Nusano announced a lutetium-177 (Lu-177) supply agreement with Australian targeted radiotherapy company GlyTherix for the new facility. GlyTherix is developing a radiopharmaceutical that combines Lu-177 with an antibody that targets glypican-1, a protein found in aggressive cancers, with plans to launch a phase I trial.
Boston-based pharmaceutical company Ratio Therapeutics also entered a long-term, multi-isotope supply agreement in June, according to Nusano.
Utah Gov. Spencer Cox was on hand to welcome the opening. Production will begin in late 2025, and under full operations, the facility will be capable of producing more than 40 radioisotopes applicable to the life sciences industry, the company said.
Via X, Cox said the plant represents a $300 million investment.
